V8 Peptides — Engineered Performance
Research Library
Sermorelin Research Guide: Question Map and Sources
SermorelinOverview

Sermorelin Research Guide: Question Map and Sources

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

Where should a researcher start with sermorelin? Start with the 1982 isolation and sequence papers on growth-hormone-releasing factor, then the receptor cloning and cAMP studies, and read each finding together with its stated conditions. Sermorelin is the 1-29 amide of GHRH; much of the literature used the native 44-residue hormone or modified analogs, so check which molecule each paper tested.

Most "guides" to a research peptide summarize its properties in a list. This one is organized the way an experiment begins, with a question, and it says for each what kind of study answers it, which sources are primary and where the evidence ends. For laboratory research use only; not for human consumption.

How to use this guide

Sermorelin is a 29-residue peptide with a long paper trail and a short list of things that are actually known. This guide is organized by research question instead of by topic, because that is how an experiment starts: you have a question, and you need to know which kind of study answers it, which published papers exist, and what the molecule's own limits are. Each section ends with a pointer to a library page. Product facts come from the live sermorelin product page: GHRH (1-29) analog, lyophilized powder in 5 mg and 10 mg sizes, ≥98% purity by HPLC, formula C149H246N44O42S, stored refrigerated at 2–8 °C or at −20 °C for the long term and protected from heat, moisture and light. The biology is introduced in the sermorelin overview.

Question map

The table links each common research question to the kind of evidence that answers it and the sources a reader should start from.

If your question is...The relevant evidence typeStart with
What is the molecule and where did it come from?Isolation and sequence papers, 1982–1984Guillemin 1982 [1]; Spiess 1982 [2]; Ling 1984 [3]
Which receptor and signal does it use?Receptor cloning; cAMP in pituitary cellsMayo 1992 [4]; Bilezikjian and Vale [5]
What does it release and how fast?Primary pituitary cell culturesBrazeau 1982 [6]
What limits its persistence?Plasma degradation; PEGylation and albumin-conjugate studiesFrohman 1986 [7]; Jetté 2005 [8]
Does the schedule of exposure matter?Rat infusion and pulse studiesBorski [9]; Kovács [10]
Does it act outside the pituitary?Receptor splice variants; perfused organsHalmos 2025 [11]; Penna 2013 [12]
How do I verify what is in the vial?Analytical chemistry and quality-specification literatureVergote 2009 [13]; Roux 2008 [14]

Two cautions about reading the table. A single citation answers only the narrow question next to it, and a claim built from several rows needs each row to be checked separately. And "sermorelin" is shorthand: much of the early literature used the native 44-residue hormone, and the 1-29 amide enters most often as a comparator.

Facts that are settled

Some statements are as firm as peptide endocrinology gets, and each rests on a primary paper.

  • Growth-hormone-releasing factor was isolated from human pancreatic tumors that had caused acromegaly and had a 44-residue structure; the synthetic replicate had full activity in vitro and in vivo [1].
  • The 1-29 amide had in vitro activity equivalent to longer forms in the sequence analysis, indicating the C-terminal region does not contribute significantly to intrinsic activity or potency [2].
  • The same hormone is made in the human hypothalamus [3], and the rat hypothalamic version is a different, 43-residue peptide with 67% homology to the human tumor peptide [15].
  • The pituitary receptor is a G protein-coupled receptor related to the secretin and VIP receptors, and its stimulation raises cAMP [4][5].
  • Somatostatin blocks GH release; in cultured pituitary cells it blocks release completely but only partly attenuates cAMP [5].
  • A receptor point mutation (Asp60 to Gly) produces a hypoplastic pituitary in the little mouse [16].
  • Plasma converts the 44-residue hormone to an inactive 3-44 product, cleaved at the N-terminus [7].

Facts that depend on conditions

A second group of statements is true only under stated conditions, and the conditions are part of the finding.

StatementConditions under which it was reportedWhere it fails
Pulsatile exposure is effective, continuous is notFemale rats, GHRH infusions and pulses at a 1.5-hour frequency [9]Other species, other analogs, other schedules
High continuous exposure desensitizesRats, a 1-30 amide analog [10]Unmodified sermorelin; humans
Response is larger at the peak of the GH rhythm than the troughFreely moving male rats with endogenous somatostatin [17]Cultures without somatostatin
Co-activation of GHS and GHRH receptors doubles cAMPCells expressing both transfected receptors [18]Native pituitary cells and in vivo
A PEGylated 1-29 amide prolongs GH responseRats and pigs [19]Unmodified sermorelin, other PEG sites

A reader who carries a condition-dependent finding into a different context has changed the claim. This is the most common error in secondary descriptions of the literature.

What is not known from the sources reviewed

Three gaps are worth stating plainly, because they are the places where unsupported claims tend to appear.

  • A sermorelin-specific half-life in a named culture medium. The plasma values concern the native hormone, and no medium value was found.
  • Net peptide content and counterion of a given lot. The product page lists purity by HPLC but not counterion; the certificate is the place to look. Trifluoroacetate at 10-8 to 10-7 M reduced proliferation in osteoblast cultures, and the authors advised converting such peptides to a hydrochloride or equivalent salt before testing biological effects [14][20].
  • Organ-level function of sermorelin itself. The perfused heart study used GHRH, not sermorelin [12].

Reading order for a new reader

  1. Orientation. The overview and the library article on amino acid sequence notation.
  2. Related compounds. CJC-1295 versus sermorelin for the substitution pattern, tesamorelin versus sermorelin for the stabilized 44-residue analog, and sermorelin versus ipamorelin for the secretagogue route.
  3. Primary papers. Start with the three isolation papers [1][2][3], then the receptor [4] and the cAMP study [5].
  4. Handling. How to reconstitute a lyophilized peptide, storing research peptides and what lyophilization is.
  5. Verification. How to read a COA, understanding HPLC purity, HPLC versus mass spectrometry and sermorelin purity testing.

Glossary of terms that recur

TermMeaning in this literature
GHRH, GRF, GRH, somatocrininNames for the same hypothalamic hormone; the naming reflects the group that isolated it [1][6]
GHRH (1-29)The first 29 residues, amidated; sermorelin
GRF(3-44)The inactive product of N-terminal peptidase cleavage [7]
hpGRF, rhGRFHuman pancreatic-tumor and rat hypothalamic forms
GHS, GHS-RGrowth hormone secretagogues and their receptor, a distinct GPCR [18]
SV1Splice variant 1 of the GHRH receptor, the closest to full-length [11]
PEGylationCovalent attachment of polyethylene glycol to extend persistence [19]
CounterionAcetate, trifluoroacetate or other anion that balances the peptide charge [14]

For arithmetic, use the calculator; the COA library lists published certificates; related compounds are in the shop.

All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.

Frequently asked questions

What is a good first paper to read on sermorelin?

The 1982 isolation paper on growth-hormone-releasing factor from a human pancreatic tumor, followed by the sequence analysis that showed the 1-29 amide had equivalent in vitro activity.

What is the difference between GHRH and GRF?

They are names for the same hormone, used by different groups; GHRH is the standard name now.

How is sermorelin related to native GHRH?

It is the first 29 residues of the 44-residue human hormone with an amidated C-terminus.

Which receptor does it act on?

The pituitary GHRH receptor, a G protein-coupled receptor related to the secretin and VIP receptors, which raises cAMP.

What do rat studies say about timing?

GH responses were larger at the peak of the GH rhythm than at the trough, and removing somatostatin eliminated the difference.

Does the guide recommend a use?

No. It points to published findings and the conditions under which they were reported.

Where do I find out about the salt form of a vial?

On the certificate or from the supplier. The product page does not list a counterion.

What is not known?

A sermorelin-specific half-life in culture medium and organ-level function of sermorelin itself were not found in the sources reviewed.

Is this guide a substitute for the primary literature?

No. It maps the literature and states where each claim comes from; read the paper before citing the claim.

Related reading: Sermorelin in 2026: What Recent Research Adds, Sermorelin Research Profile: Formula, Mass, Stability, CJC-1295 vs Sermorelin: Substitutions and Assay Design.

References

  1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-7. doi:10.1126/science.6812220
  2. Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982;21(24):6037-40. doi:10.1021/bi00267a002
  3. Ling N, Esch F, Böhlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci U S A. 1984;81(14):4302-6. doi:10.1073/pnas.81.14.4302
  4. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-44. doi:10.1210/mend.6.10.1333056
  5. Bilezikjian LM, Vale WW. Stimulation of adenosine 3',5'-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology. 1983;113(5):1726-31. doi:10.1210/endo-113-5-1726
  6. Brazeau P, Ling N, Böhlen P, Esch F, Ying SY, Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc Natl Acad Sci U S A. 1982;79(24):7909-13. doi:10.1073/pnas.79.24.7909
  7. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
  8. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286
  9. Borski RJ, Tsai W, Demott-Friberg R, Barkan AL. Induction of growth hormone (GH) mRNA by pulsatile GH-releasing hormone in rats is pattern specific. Am J Physiol Endocrinol Metab. 2000;278(5):E885-91. doi:10.1152/ajpendo.2000.278.5.E885
  10. Kovács M, Fáncsik A, Mezö I, Teplán I, Flerkó B. Effects of continuous and repetitive administration of a potent analog of GH-RH(1-30)NH2 on the GH release in rats. Neuroendocrinology. 1994;59(4):371-9. doi:10.1159/000126680
  11. Halmos G, Schally AV, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025;26(3):343-352. doi:10.1007/s11154-025-09952-x
  12. Penna C, Settanni F, Tullio F, Trovato L, Pagliaro P, Alloatti G, et al. GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology. 2013;154(4):1624-35. doi:10.1210/en.2012-2064
  13. Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
  14. Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-9. doi:10.1002/psc.951
  15. Spiess J, Rivier J, Vale W. Characterization of rat hypothalamic growth hormone-releasing factor. Nature. 1983;303(5917):532-5. doi:10.1038/303532a0
  16. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 1993;364(6434):208-13. doi:10.1038/364208a0
  17. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-7. doi:10.1210/endo-115-5-1952
  18. Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. doi:10.1210/en.2002-220670
  19. D'Antonio M, Louveau I, Esposito P, Bertolino M, Canali S. Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. Growth Horm IGF Res. 2004;14(3):226-34. doi:10.1016/j.ghir.2003.12.014
  20. Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-83. doi:10.1152/ajpendo.1999.277.5.E779

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.